NO20055907L - Fremgangsmate for behandling av en angstforstyrrelse - Google Patents

Fremgangsmate for behandling av en angstforstyrrelse

Info

Publication number
NO20055907L
NO20055907L NO20055907A NO20055907A NO20055907L NO 20055907 L NO20055907 L NO 20055907L NO 20055907 A NO20055907 A NO 20055907A NO 20055907 A NO20055907 A NO 20055907A NO 20055907 L NO20055907 L NO 20055907L
Authority
NO
Norway
Prior art keywords
disorder
treating
anxiety disorder
adenosine
receptor antagonist
Prior art date
Application number
NO20055907A
Other languages
English (en)
Inventor
Hiroshi Kase
Naoki Seno
Shizuo Shiozaki
Minoru Kobayashi
Junya Kase
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Publication of NO20055907L publication Critical patent/NO20055907L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Angstforstyrrelser, slike som panikkforstyrrelse, agorafobi, obsessiv-kompulsiv forstyrrelse, sosial fobi, post-fraumatisk sfressforstyrrelse, generell angstforstyrrelse, spesifikk fobi eller lignende, behandles for adminisfrasjon av en effektiv mengde av minst en adenosin A2A reseptorantagonist til en pasient som frenger det, eventuelt i kombinasjon med et anxiolytisk middel forskjellig fra adenosin A2A reseptorantagonisten.
NO20055907A 2003-06-10 2005-12-13 Fremgangsmate for behandling av en angstforstyrrelse NO20055907L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50904603P 2003-06-10 2003-06-10
US53279303P 2003-12-24 2003-12-24
PCT/JP2004/008486 WO2004108137A1 (en) 2003-06-10 2004-06-10 A method of treating an anxiety disorder

Publications (1)

Publication Number Publication Date
NO20055907L true NO20055907L (no) 2005-12-13

Family

ID=33514319

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055907A NO20055907L (no) 2003-06-10 2005-12-13 Fremgangsmate for behandling av en angstforstyrrelse

Country Status (15)

Country Link
US (2) US8202869B2 (no)
EP (1) EP1631294B1 (no)
JP (1) JP4778894B2 (no)
KR (1) KR20060037252A (no)
CN (1) CN1787821A (no)
AT (1) ATE481101T1 (no)
AU (1) AU2004244906A1 (no)
BR (1) BRPI0411120A (no)
CA (1) CA2528710C (no)
CO (1) CO5640121A2 (no)
DE (1) DE602004029160D1 (no)
EA (1) EA200501924A1 (no)
MX (1) MXPA05013148A (no)
NO (1) NO20055907L (no)
WO (1) WO2004108137A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150080013A (ko) * 2002-01-28 2015-07-08 교와 핫꼬 기린 가부시키가이샤 운동성 질환에 걸린 환자의 치료용 조성물
US10042980B2 (en) 2005-11-17 2018-08-07 Gearbox Llc Providing assistance related to health
US20070136092A1 (en) * 2005-11-30 2007-06-14 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging
US10296720B2 (en) 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US20070124176A1 (en) * 2005-11-30 2007-05-31 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US7994190B2 (en) 2006-11-01 2011-08-09 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
MX2010000938A (es) * 2007-07-23 2010-07-01 Synosia Therapeutics Inc Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del ácido 4-hidroxi-4-metil-piperidin-1-carboxílico para el tratamiento del trastorno por estrés postraumático.
UA113383C2 (xx) 2009-09-02 2017-01-25 Терапевтичний агент для лікування тривожних розладів
UA110097C2 (uk) 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою
US8609162B2 (en) * 2012-10-04 2013-12-17 Invivo Beverages Llc Integrated neuromodulation system for mood enhancement of a living human subject
CN105770563A (zh) * 2016-04-22 2016-07-20 孙建 一种治疗焦虑症的中药制剂及其制备方法
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
JP7391046B2 (ja) 2018-05-18 2023-12-04 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としての縮合ピリミジン誘導体
CN117304191A (zh) 2018-07-05 2023-12-29 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2022167778A1 (en) 2021-02-02 2022-08-11 Haiku Therapeutics Ltd Ebselen as adenosine receptor modulator
KR102567684B1 (ko) 2023-01-10 2023-08-18 주식회사 웨이센 디지털 표현형 특징을 이용한 사회 불안장애 분석방법 및 장치
KR102594242B1 (ko) 2023-01-10 2023-10-27 주식회사 웨이센 디지털 표현형 특징을 이용한 사회 불안장애 분석방법 및 장치

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06104666B2 (ja) * 1986-09-30 1994-12-21 チバ―ガイギー アクチェンゲゼルシャフト ２―置換―ｅ―縮合―〔１，２，４〕トリアゾロ〔１，５―ｃ〕ピリミジン類及びそれを含有する医薬組成物
US5047534A (en) * 1990-03-26 1991-09-10 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents
US5484920A (en) 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
US5543415A (en) 1992-07-08 1996-08-06 Kyowa Hakko Kogyo Co., Ltd. Antidepressants
ATE325610T1 (de) 1997-09-05 2006-06-15 Kyowa Hakko Kogyo Kk Xanthinderivative zur behandlung von hirnischämie
KR20010087361A (ko) 1998-09-22 2001-09-15 히라타 다다시 [1,2,4]트리아졸로[1,5-ｃ]피리미딘 유도체
WO2000069464A1 (fr) * 1999-05-12 2000-11-23 Fujisawa Pharmaceutical Co., Ltd. Nouvelle utilisation
MY132006A (en) * 2000-05-26 2007-09-28 Schering Corp ADENOSINE A2a RECEPTOR ANTAGONISTS
WO2003022283A1 (en) 2001-09-13 2003-03-20 Schering Corporation Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
MXPA04003474A (es) * 2001-10-15 2004-07-30 Schering Corp Imidazo (4,3-e)-1,2,4-triazolo(1,5-c) pirimidinas como antagonistas del receptor de adenosina a2a.
US20030119831A1 (en) * 2001-11-20 2003-06-26 Hartz Richard A. 3,7-dihydro-purine-2,6-dione derivatives as CRF receptor ligands
US20060128694A1 (en) * 2002-12-19 2006-06-15 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders

Also Published As

Publication number Publication date
US20120232089A1 (en) 2012-09-13
JP2006527264A (ja) 2006-11-30
US8592420B2 (en) 2013-11-26
CA2528710A1 (en) 2004-12-16
EP1631294A1 (en) 2006-03-08
CA2528710C (en) 2012-04-17
CN1787821A (zh) 2006-06-14
AU2004244906A1 (en) 2004-12-16
US20060281770A1 (en) 2006-12-14
WO2004108137A1 (en) 2004-12-16
CO5640121A2 (es) 2006-05-31
JP4778894B2 (ja) 2011-09-21
BRPI0411120A (pt) 2006-07-18
EP1631294B1 (en) 2010-09-15
KR20060037252A (ko) 2006-05-03
ATE481101T1 (de) 2010-10-15
EA200501924A1 (ru) 2006-06-30
MXPA05013148A (es) 2006-03-17
US8202869B2 (en) 2012-06-19
DE602004029160D1 (no) 2010-10-28

Similar Documents

Publication Publication Date Title
NO20055907L (no) Fremgangsmate for behandling av en angstforstyrrelse
DE60305052D1 (de) Thienopyrrolyl und furanopyrrolyl verbindungen und deren verwendung als histamin h4 rezeptor liganden
NO20061239L (no) Fremgangsmater og reagenser for behandling av immunoinflammatoriske forstyrrelser
ATE490984T1 (de) Methode zur produktion und evaluierung der zytotoxizität von kir2dl nk-rezeptor antikörpern
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
ATE464303T1 (de) Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
BRPI0414918A (pt) compostos de benzoimidazola
ATE541859T1 (de) Humane anti-interferon-gamma-antikörper und verfahren zu ihrer verwendung
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
MX2010005047A (es) Inhibidores de aldh-2 en el tratamiento de enfermedades psiquiatricas.
PT2046373E (pt) Oxalato descarboxilase cristalizada e métodos de utilização
DE602006017574D1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
BRPI0411471A (pt) método para produzir um não-trançado fibroso e não-trançado fibroso
DK1480627T3 (da) Fremgangsmåder til mindskelse af angiogenese
WO2006080549A3 (en) Method and composition for treating central nervous system disorders
WO2007053796A3 (en) Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
BRPI0612424A2 (pt) composiÇÕes e mÉtodos para tratar condiÇÕes relacionadas com a sinalizaÇço da efrina com cupredoxinas
TW200507840A (en) Method of treating multiple myeloma
ATE446299T1 (de) Verfahren zur herstellung von 7-ethyl-10- hydroxycamptothecin
AR042890A1 (es) Metodo de tratamiento del ojo seco con una composicion oftalmica que contiene un compuesto macrolido
NO20083034L (no) Farmasoytiske formuleringer av escitalopram med modifisert og pulserende frigivelse
WO2007013962A3 (en) Rapid onset and short term modafinil compositions and methods of use thereof
ATE496047T1 (de) Phenylen-bis-oxazolidin-derivate und ihre verwendung als antikoagulantien
NO20053911L (no) Diazepinderivater som er nyttige som LFA inhibitorer.
ATE531698T1 (de) 4-aminocarbonylamino-substitutierte imidazolverbindungen mit antiviraler wirkung

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application